Peter Johann

Peter Johann is an accomplished entrepreneur and executive with extensive experience in the biotechnology and life sciences sectors. As the Founder, Chairman, and CEO of Lumendi since January 2015, Peter has led various innovative initiatives. Peter is also the Managing General Partner at NGN Capital since August 2004 and serves on the boards of several companies, including Vivaldi Biosciences and Exosome Diagnostics, the latter of which was acquired by BioTechne. Peter has held significant roles in other organizations, such as Zenith Epigenetics Ltd. and Resverlogix Corp., and has contributed to various committees, including compensation and audit committees, throughout a career marked by the successful navigation of IPOs and acquisitions. Peter holds a degree from the Technical University of Munich, where studies were completed between 1977 and 1985.